Abstract
Introduction
The prevalence of diabetes mellitus (DM) is increasing through-out the world and mostly contributed by type 2 diabetes mellitus. 1 DM is the leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) both in developed and developing countries. [2] [3] [4] [5] [6] [7] Diagnosis of CKD among patients with DM merits considerable changes in antidiabetic management, cardiovascular risk modification and addressing other metabolic issues including chronic kidney diseasemineral and bone disorders (CKD-MBD). Treatment of CKD-MBD is an integral component of CKD management. Serum intact parathyroid hormone (iPTH) is the key target for management of CKD-MBD. 8 Hyperglycaemia suppresses PTH secretion in life 9, 10 and in experiments. 11 CKD patients with DM have low iPTH when compared with non-diabetic CKD patients. 9, 10 Diabetic CKD patients with poor DM control have lower iPTH, irrespective of treatment modality (with or without dialysis). 9, 10, [12] [13] Low iPTH is reported to cause adynamic bone disease. 14 Data regarding HbA1c and its relation with iPTH in CKD stages 3-5 predialysis patients are limited. This study was designed to evaluate serum Ca, PO4, alkaline phosphatase, iPTH, HbA1c level among diabetic CKD stages 3-5 predialysis patients and to evaluate the relationship between iPTH and HbA1c among them.
Methods
This cross-sectional study was conducted in Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM) General Hospital, Dhaka, Bangladesh from January 2013 to December 2014. Diabetic patients suffering from CKD stages 3-5, irrespective of their treatment modality relating to CKD-MBD, who were not on dialysis, were consecutively and purposively included in this study. Patients with diagnosed parathyroid disorders, history of parathyroid surgery, primary bone disease or metastatic bone disease and diagnosed genetic or hereditary conditions were excluded from the study. Along with base-line characteristics, laboratory data including HbA1c and iPTH levels were recorded for all patients. HbA1c was done by BIO-RAD variant (modified HPLC method) and iPTH was detected by Chemiluminescent Micropartical Immunometric Assay (CMIA). CKD was diagnosed and staging done as per Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines 2012. 8 eGFR was estimated by using chronic kidney disease-epidemiology (CKD-EPI) creatinine based formula. 15 Data were analyzed by using SPSS version 20.0 and Pearson's correlation test was applied to evaluate the relationship between HbA1c and iPTH.
Results
Total patients were 306 with slight male predominance (male 166, 54.2%). Mean age of the study participants, mean duration of DM and mean duration of CKD were 56.5±11.3, 12.8±7.6 and 2.9±1.7 years respectively. Among the study population, 49 (16.0%) were in CKD stage 3, 90 (29.4%) in CKD stage 4 and rest 167 (54.6%) in CKD stage 5. Two-thirds (202, 66%) of the study participants were receiving calcium and vitamin D, 52 (17%) were receiving only calcium and equal number (52, 17%) were not on any treatment regarding CKD-MBD. Base-line biochemical parameters are presented in Table I . Table II . Glycaemic targets (HbA1c <7%) were rarely achieved among the study subjects (Table III) and majority of the study participants did not achieve iPTH targets 16 irrespective of treatment modality (Table IV and Table V) . On correlation analysis, HbAlc had a significant negative correlation with iPTH(r=-0.002) (Figure 1 ). 
Discussion
The complex pathophysiology of CKD-MBD is less well understood and much less studied in developing countries like ours. CKD-MBD has two distinct components; high PTH related to high bone turn over and low PTH resulting in adynamic bone disease. 14 Diabetic patients 17 and those with poor glycaemic control 9,12,13 are reported to have low iPTH and at high risk of vascular calcification 18 , accelerated peripheral vascular disease 19 and adverse cardiovascular events.
From the results of current study, it is evident that only a few patients could achieve iPTH targets, irrespective of treatment modality. None of them were checked for PTH before starting treatment and none were monitored.
HbA1c were rarely achieved in this study, in spite of its limitations in assessing glycaemic control in patients with CKD. American Diabetic Association has relaxed HbA1c targets of patients with CKD with comorbidities 20 ; still, most patients remained beyond control. Current study had some potential limitations. It was a single center study, included small number of patients and we could not go for bone biopsy. HbA1c may not be the only indicator of glycaemic control in patients with CKD.
Figure 1. Relationship between HbA1c and PTH Level
In conclusion, the results of current study showed that most diabetic CKD stages 3-5 predialysis patients had poor glycaemic control and most patients did not achieve their iPTH targets. Assessment of CKD patients regarding CKD-MBD remained grossly substandard. HbAlc had negative correlation with iPTH. As iPTH level is influenced by presence and control of DM, the targets of iPTH in CKD stages 3-5 in general, as recommended in existing guidelines, may not be appropriate in diabetic CKD patients and this issue merits further investigation.
